Federated Hermes
KRYS icon

Federated Hermes’s Krystal Biotech KRYS Stock Holding History

Federated Hermes’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Buy
43,848
+8,353
+24% +$2.5M 0.02% 548
2026
Q1 		$9.17M Buy
35,495
+954
+3% +$254K 0.01% 664
2025
Q4 		$8.52M Buy
34,541
+10,560
+44% +$2.22M 0.01% 671
2025
Q3 		$4.23M Sell
23,981
-18,762
-44% -$2.81M 0.01% 771
2025
Q2 		$5.88M Buy
42,743
+29,962
+234% +$4.4M 0.01% 691
2025
Q1 		$2.3M Sell
12,781
-267
-2% -$44.9K 0.01% 903
2024
Q4 		$2.04M Buy
13,048
+229
+2% +$40.6K ﹤0.01% 927
2024
Q3 		$2.33M Buy
+12,819
New +$2.47M 0.01% 898
2023
Q4 		– Sell
-5
Closed -$580 – 2121
2023
Q3 		$580 Hold
5
– – ﹤0.01% 2034
2023
Q2 		$587 Hold
5
– – ﹤0.01% 2047
2023
Q1 		$400 Sell
5
-1
-17% -$79 ﹤0.01% 2084
2022
Q4 		$475 Hold
6
– – ﹤0.01% 2087
2022
Q3 		$1K Hold
6
– – ﹤0.01% 2051
2022
Q2 		$1K Hold
6
– – ﹤0.01% 2050
2022
Q1 		$1K Sell
6
-654
-99% -$40.8K ﹤0.01% 2097
2021
Q4 		$46K Sell
660
-7,451
-92% -$434K ﹤0.01% 1799
2021
Q3 		$423K Sell
8,111
-145,503
-95% -$8.61M ﹤0.01% 1542
2021
Q2 		$10.4M Buy
153,614
+19,623
+15% +$1.37M 0.02% 643
2021
Q1 		$10.3M Buy
+133,991
New +$9.74M 0.02% 653
2019
Q2 		– Sell
-124
Closed -$4K – 2191
2019
Q1 		$4K Sell
124
-834
-87% -$19.7K ﹤0.01% 2000
2018
Q4 		$20K Hold
958
– – ﹤0.01% 1771
2018
Q3 		$17K Buy
+958
New +$16.1K ﹤0.01% 1868

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Federated Hermes's KRYS Position: Q2 2026 in Review

Federated Hermes increased its Krystal Biotech (KRYS) stake by 24% in Q2 2026, buying an estimated $2.5M and bringing the position to 43,848 shares worth $16.3M. The position accounts for 0.02% of the portfolio, ranked #548.

Federated Hermes first reported a position in KRYS in Q3 2018 and has held it in 22 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Federated Hermes held 43,848 shares of Krystal Biotech worth $16.3M as of Q2 2026.
  • Federated Hermes bought 8,353 Krystal Biotech shares in Q2 2026, an estimated $2.5M.
  • Krystal Biotech made up 0.02% of Federated Hermes's portfolio in Q2 2026, its #548 holding.
  • Federated Hermes first reported a position in Krystal Biotech in Q3 2018 and has held it in 22 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.